CDK4/6 inhibitor after breast cancer surgery
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests whether a CDK4/6 inhibitor given after surgery can help prevent breast cancer from coming back. It is for people with HR-positive, HER2-negative breast cancer that has not spread to other parts of the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with breast cancer that is HR-positive and HER2-negative
- The cancer has not spread to other parts of your body or come back locally
- You are able to be active and care for yourself (ECOG score 0-3)
- You are planning to take a CDK4/6 inhibitor after surgery as recommended by your doctor
- You are not pregnant or nursing, and you can swallow pills
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how CDK4/6 medicines fit into treatment for people with advanced hormone receptor–positive breast cancer that cannot be cured with surgery or radiation. It may help doctors understand the best way to use these medicines for disease that has returned or spread.
This trial tests whether adding a CDK4/6 inhibitor (a type of targeted pill) to standard hormone therapy after surgery can lower the risk of breast cancer coming back in women with high-risk, hormone-receptor-positive, HER2-positive early breast cancer.
This study tests whether some patients with early-stage, hormone-positive breast cancer can safely skip chemotherapy and just use hormone therapy plus a CDK4/6 inhibitor pill after surgery. If you qualify, you may avoid chemo side effects while still reducing the chance of the cancer coming back.
This study looks at how well CDK4/6 inhibitors work in older adults with breast cancer who are taking these drugs after surgery to help prevent the cancer from coming back. It will follow patients over time to learn more about their experiences.
This study looks at how well CDK4/6 inhibitors combined with hormone therapy work in real-world settings for people with a certain type of advanced breast cancer (HR+/HER2-). It aims to understand the best treatment path and what happens next.
This study looks at how well CDK4/6 inhibitors (a type of targeted therapy) work in real-world patients with HR+/HER2- advanced breast cancer. By collecting medical data from people treated at this hospital, doctors hope to learn more about the effectiveness and safety of these drugs in everyday practice.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.